AdjuTec Pharma AS has partnered with Venus Remedies Limited (India) to advance research on APC-148, a novel technology designed to combat Antimicrobial Resistance (AMR). Venus Remedies will conduct pre-clinical trials to evaluate APC-148’s effectiveness in restoring the potency of antibiotics against multidrug-resistant bacteria.

APC-148, AdjuTec Pharma’s leading resistance-breaking technology, selectively dismantles bacterial resistance mechanisms, allowing existing antibiotics to regain their efficacy. Currently in Phase 1 clinical trials, this breakthrough aims to address the growing global AMR crisis, which causes 1.3 million deaths annually and is projected to reach 39 million by 2050 if left uncontrolled.

As part of this initiative, Venus Remedies will test APC-148 alongside multiple antibiotics using its extensive collection of clinical isolates from the GASAR study. This effort aligns with the UN’s ‘One Health’ mission and highlights the urgent need for innovative AMR solutions, particularly in India, where AMR-related deaths exceeded 300,000 in 2019, significantly impacting newborns.

Leaders from both companies expressed enthusiasm for the collaboration, emphasizing their shared goal of developing advanced solutions to fight antibiotic resistance. This partnership underscores a commitment to innovation-driven research, paving the way for more effective treatments against resistant infections worldwide.